Manufacturing & Flex Real Estate: Reshoring, R&D, and the 2024–2026 Capex Wave

Key Takeaways

Two Asset Classes, One Label

Manufacturing and flex sit at the two ends of the industrial spectrum, and they get lumped together as "industrial" on every cap-rate sheet that hasn't been updated since 2019. Manufacturing real estate is closer to single-tenant net lease: credit underwriting against a Tier-1 corporate tenant, 10–25 year initial term, heavy specialized infrastructure, tenant capex investment dwarfing the landlord basis. Flex real estate is closer to multi-tenant office: 25–50% office buildout, shorter terms, hybrid R&D / light manufacturing / lab / assembly use, mid-market and small-tenant credit, operational asset management. Neither underwrites like the modern distribution warehouse on the same broker pitch deck. The 2024–2026 reshoring wave has changed the manufacturing side meaningfully; the post-2024 biotech R&D reset has reshaped the flex side just as much.

The reshoring narrative is the loudest single story in industrial CRE since e-commerce. Per the Reshoring Initiative, 2.1 million US manufacturing jobs have been announced via reshoring and FDI since 2010, with 244,000 in 2024 alone and 88% of the 2024 cohort in high or medium-high tech industries. The Semiconductor Industry Association counts 140+ announced projects across 30 states totaling more than $645B in semiconductor and adjacent investment. The SelectUSA program reports $400B+ in facilitated FDI since inception. CHIPS Act tranches, IRA advanced-manufacturing tax credits, and state-EDC incentive stacks have moved a generation of corporate capex into US soil.

The institutional discipline is to read the announcement-side honestly. Per IoT Analytics analyzing Census Bureau Construction Spending data, US manufacturing construction spending has declined steadily since its mid-2024 peak — driven by a 44% pullback in electronics and semiconductor fab spending. Ex-electronics, manufacturing construction is up only 5.6% since the start of tariffs. Intel's Ohio One fab has slipped from 2025 to 2030–2031. Samsung's Taylor, Texas fab is more than 90% complete and the company is, by its own description, "in no hurry" to install equipment. Stellantis took €22.2B in H2 2025 reset charges and transferred the NextStar Energy battery JV to LG. The Reshoring Initiative's own forward look projects 174,000 announced jobs in 2025 versus 244,000 in 2024 — a meaningful deceleration. The narrative is real, and the delivery is uneven, and the institutional underwriter has to hold both.

What follows is the practitioner reference for the manufacturing & flex slice of industrial CRE. We walk the industrial spectrum end to end, distinguish manufacturing CTL underwriting from flex/R&D operational underwriting, ground the reshoring story in the dataset rather than the narrative, walk the biotech R&D Cambridge vacancy reset that is the freshness wedge on the flex side, and close with a dual worked example — a Phoenix advanced-manufacturing CTL on one end and a Cambridge Kendall Square biotech R&D flex on the other. Two deals labeled "industrial." Two completely different underwriting paths. Cap rates 75 basis points apart, buyer pools that barely overlap, and the 2024–2026 macro hitting each from opposite sides.

The Industrial Spectrum

The institutional industrial taxonomy is a continuum, not a binary. The collapsing of "industrial" into one column on the cap-rate sheet conceals five distinct subtypes with materially different office shares, lease terms, tenant profiles, TI requirements, and cap-rate ranges. The table below is the spine; every subsequent section of this article returns to it.

Table 1 — The five-subtype industrial spectrum. Cap-rate ranges from CBRE 2026 Industrial Outlook, Cushman & Wakefield Q1 2026 MarketBeats, NAIOP Industrial Space Demand Forecast Q1 2026, and Bridge Investment Group / FNRP net-lease comp work. TI / fit-out PSF triangulated against the Cushman & Wakefield Life Sciences US Fit-Out Cost Guide and clean-room cost references from ACH Engineering and SEMI member capex disclosures. The boldface rows are this article's central pair: flex/R&D and advanced manufacturing.

The 2024–2026 Reshoring Narrative — Factually

Treat the reshoring story as a dataset, not a politics. The 2022 CHIPS and Science Act authorized $52.7B in semiconductor incentives plus a 25% advanced-manufacturing investment tax credit. The 2022 Inflation Reduction Act layered EV-battery and advanced-energy manufacturing credits on top. State EDCs in Arizona, Texas, Ohio, Georgia, the Carolinas, Indiana, Michigan, and Tennessee have written nine- and ten-figure incentive packages against the federal stack. The capital intent, regardless of one's view of the policy, is concrete.

Announced volumes — what the data says

Per the Reshoring Initiative 2024 Annual Report (Harry Moser's dataset, the most-cited source on US reshoring activity), 244,000 manufacturing jobs were announced in 2024 via reshoring and FDI — cumulative 2.1+ million jobs since 2010. 88% of 2024 announcements landed in high or medium-high tech industries (90% in early 2025 data). The 2025 Reshoring Survey flags 2.1M unfilled US manufacturing jobs forecast by 2030 — the labor constraint that increasingly governs site selection above land cost or incentive depth.

Per the Semiconductor Industry Association, the CHIPS-era pipeline carries 140+ announced semiconductor and adjacent investments across 30 states totaling more than $645.3B. The headline projects are familiar to any industrial acquirer: TSMC's three-fab Phoenix complex (Fab 21 phase 1 in volume since late 2024; phase 2 equipment install Q3 2026, production 2027); Samsung's Taylor, Texas fab; Intel's Ohio One in New Albany; Micron's Boise and Clay, NY expansions; GlobalFoundries' Malta, NY expansion; and the Asian-supply-chain follow-on of equipment, materials, and packaging investments around each anchor. The EV battery cohort layers in Ford BlueOval City (Stanton, TN, with SK On), GM Ultium (Lordstown, Spring Hill, Lansing), the Stellantis-LG NextStar Energy plant (Windsor / Indiana), and the Hyundai-LG Metaplant in Bryan County, GA. Biotech reshoring — mid-cycle Eli Lilly Lebanon, IN ($9B), Novo Nordisk Clayton, NC, AstraZeneca Maryland, and the federal-BARDA-funded contract-manufacturing buildout — layers in another vertical.

Per the SelectUSA program at the US Department of Commerce, the FDI slice of this aggregate has supported 270K+ jobs and more than $400B of facilitated investment since the program's inception. The Bank of America Institute documents a concentration of the activity in the South and Midwest — the Sun Belt reshoring belt running from the Carolinas through Georgia, Alabama, Tennessee, Kentucky, Indiana, Ohio, and the Texas triangle. Per the CBRE 2026 US Industrial Outlook, Louisville, Nashville, Cincinnati, Chicago, Detroit, and Kansas City are the named manufacturing-expansion markets in 2026 — the inland reshoring corridor — with Phoenix, Austin, Atlanta, and the Carolinas anchoring the semiconductor and EV battery clusters.

The translation to CRE demand

Per the JLL Shifting Trade Policies guide, manufacturing was 20% of JLL's industrial leasing requirements in 2024 and is projected to be 30% by 2028. JLL's own manufacturing-engagement count is up 350% since 2018. Per CBRE's 2026 Outlook, build-to-suit development increases through 2026 to meet specialized manufacturing requirements; speculative manufacturing is essentially absent. The Prologis-GIC $1.6B US build-to-suit JV formed in March 2026 with a 4.1M SF initial portfolio is the clearest 2026 institutional signal for the BTS manufacturing-and-advanced-industrial pipeline. Per Prologis' own 2026 Bold Predictions, 60%+ of 2025 industrial starts were build-to-suit, and power-ready facilities now rank in the top-three site-selection factors globally.

The Honest Tempering of the Narrative

The institutional read is that announced volume is a poor leading indicator for breaking-ground volume. Discount accordingly. The 2024–2026 dataset on the delivery side is unambiguous — and citing it is the freshness wedge that separates a serious manufacturing CRE underwriting note from a build-to-suit pitch deck.

Manufacturing construction spending has decelerated

Per IoT Analytics analyzing Census Bureau Construction Spending data, US manufacturing construction spending has declined steadily since its mid-2024 peak. The pullback is concentrated — electronics and semiconductor fab spending is down approximately 44% from the mid-2024 high. Ex-electronics, manufacturing construction is up only 5.6% since the start of tariffs — well below the headline narrative the Reshoring Initiative announcement-volume figure suggests. The 2025 Census-reported manufacturing construction-spending trajectory is the leading indicator the institutional underwriter should be tracking, not the announced-jobs figure.

The specific delays are material

Three project-level data points define the announcement-vs-delivery gap. Per CNBC and Manufacturing Dive, Intel's $28B Ohio One project was originally planned for 2025 production; it slipped to 2027, then 2030, and now to 2030–2031. Intel cited "challenges with demand and the slow rollout of US government funding under the CHIPS Act."

Per SiliconANGLE, Samsung's Taylor, Texas fab is more than 90% complete as of early 2025, but Samsung is "in no hurry" to install chipmaking equipment. A finished fab with no production date. Per Stellantis' February 2026 6-K, the company took €22.2B in H2 2025 reset charges, cancelled the Ram 1500 BEV, and transferred the NextStar Energy battery JV to LG full ownership — an EV-cycle reset that has cascaded through the broader EV battery plant CRE narrative. Ford and GM have publicly trimmed their EV battery footprints in parallel.

The bright spots

The data is not uniformly bearish. TSMC Arizona is delivering. Phase 1 has been in volume production since late 2024; phase 2 (3nm) equipment install is scheduled Q3 2026 with production 2027 — ahead of the original schedule. Per AZ Big Media, Arizona ranks #1 nationally for semiconductors with 60+ industry expansions since 2020; Q1 2026 Phoenix industrial leasing printed 7.5M SF, absorption 4.4M SF, asking rates $1.19 PSF NNN. The Phoenix cluster has emerged as the most-cited proof-point that semiconductor reshoring can deliver. Per BORDERNOW coverage, metro Phoenix industrial investment hit historic levels around the TSMC expansion. The Hyundai-LG Bryan County, GA Metaplant began EV production in 2024. Eli Lilly's advanced-manufacturing buildout in Indiana, North Carolina, and elsewhere is proceeding on schedule.

The honest forward call

Per the Reshoring Initiative's own 2025 projection, announced jobs decline from 244,000 in 2024 to 174,000 in 2025 — a 29% drop. Per the ULI / PwC Emerging Trends in Real Estate 2026 survey, "the trend is positive for manufacturing, [but] the magnitude of growth will likely plateau, with the majority of logistics real estate demand still focused on serving consumption." That is the institutional consensus call. The reshoring tailwind is real, the slope of it is moderating, and the delivery is concentrated in fewer, slower, larger projects than the announced-volume headline suggests.

Why Manufacturing Is Not Distribution

A manufacturing facility is on the cap-rate sheet under "industrial," and the broker pitch deck treats it as interchangeable with a Class A logistics box on the same Sun Belt corridor. It is not. The institutional distinction matters because the underwriting framework, the buyer pool, the debt sizing, the residual logic, and the relationship to the macro cycle are all different. Six points carry the distinction.

1. Credit underwriting, not real-estate underwriting. A manufacturing credit-tenant lease (CTL) underwrites primarily to the tenant — corporate credit, balance-sheet capex commitment to the asset, strategic role of the facility in the network. Real-estate residual matters less because re-tenanting an advanced manufacturing facility is hard. Per FNRP's CTL primer and the broader net-lease institutional literature, CTL underwriting reads more like bond credit work than like rent-roll work. The buyer pool overlaps net-lease (Realty Income, W. P. Carey, STORE Capital, Spirit) more than core industrial (Prologis, Brookfield, EastGroup), even though the asset is labeled industrial.

2. Lease term is long. 10–25 years on advanced manufacturing CTL versus 5–10 years on distribution. Tenant capex is large; the tenant won't sign short, and the landlord doesn't want short either. The lease structure pulls toward absolute net — tenant covers everything including structure and roof on the most credit-driven deals.

3. Tenant capex co-investment is the moat. A semiconductor or EV battery tenant invests $10B+ of equipment into the box. Per SEMI member capex disclosures, a single leading-edge logic fab carries $15–25B of equipment alone. That capex is, effectively, a giant security deposit that makes mid-term renewal probability much higher than a distribution tenant's. The moat is institutional — the tenant cannot move the equipment without writing off the investment.

4. Infrastructure spec is heavier and more specific. 2–5 MW utility service versus ~1 MW for a Class A distribution warehouse. 1,000+ PSF floor load versus 500 PSF. Redundant utilities, specialized HVAC (clean-room ISO classes), waste-water and chemical handling for semiconductor and pharma, heavy crane capacity for OEM auto and battery, vibration isolation for semiconductor lithography. Per ACH Engineering and triangulated against the Cushman Life Sciences Fit-Out Cost Guide, advanced clean-room build-out runs $300–600 PSF on the general spec and $600–1,000+ PSF for pharma and semiconductor scopes — a multiple of distribution's $15–25 PSF TI envelope. Per ULI/PwC and Prologis, power availability is now the binding gating constraint on site selection; users encountering 1–2 year delays for sufficient power access is now standard.

5. Build-to-suit-dominant. Per Prologis Q1 2026 research, more than 60% of 2025 industrial starts were build-to-suit; the Prologis-GIC March 2026 $1.6B BTS joint venture is the institutional signal for the BTS-manufacturing pipeline ahead. Trammell Crow, Hines Industrial, Stonemont, and Industrial Realty Group are the active developer cohort. Speculative advanced manufacturing is essentially nonexistent.

6. Different geography. The manufacturing reshoring map — the Midwest belt (Louisville, Nashville, Cincinnati, Chicago, Detroit, Kansas City), Phoenix and Austin (semiconductors), Atlanta and the Carolinas (Hyundai/LG, BMW, VinFast, Toyota), Indiana (Stellantis-LG, Lilly), Tennessee (Ford BlueOval) — overlaps but does not equal the modern distribution geography. The distribution map is the inland-port + coastal-port matrix (Dallas, the Inland Empire, Atlanta, Memphis, Columbus, Indianapolis, Northeast NJ/Lehigh). Sun Belt overlap is meaningful, but the manufacturing geography is more concentrated around utility-rich and water-rich sites that the distribution map doesn't prioritize.

Flex / R&D — the Hybrid Category

Flex sits between distribution and pure office. Per Adventures in CRE and the NAIOP taxonomy, the institutional flex definition is ≥25% office buildout, with the remainder in light industrial, R&D, lab, or assembly use. The practical office share runs 25–50%, with the upper end approaching small-floor-plate office. Flex is multi-tenant, smaller-floorplate, higher-parking, and considerably more operationally intensive than distribution. The cap rate runs 100–150 basis points wider than core logistics in most markets, reflecting the operational complexity and the shorter average lease term.

Flex sub-uses — the four populations

Biotech / life-sciences R&D is the highest-value flex sub-use. The institutional submarkets — Kendall Square (Cambridge), South San Francisco, San Diego UTC, the Route 128 corridor, Princeton-NJ, and Research Triangle Park — carry cap rates that compressed to 4.5–5.25% in 2021 and have since reset wider with the 2024–2026 biotech demand pullback. Specialist sponsors dominate: Alexandria Real Estate Equities, IQHQ, Longfellow, BioMed Realty (Blackstone), Healthpeak's life-sciences book, Ventas's life-sciences book, Tishman Speyer's life-sciences platform. Lab fit-out per the Cushman Life Sciences Fit-Out Cost Guide runs $250–500+ PSF on the institutional spec.

Tech R&D is the Silicon Valley archetype. Cushman & Wakefield's Q1 2026 Silicon Valley R&D MarketBeat prints 13.0% vacancy (+30 bps QoQ, +70 bps YoY) — soft but not collapsed. Tech-R&D demand correlates to venture funding and corporate R&D capex; the AI infrastructure cycle is a tailwind on certain submarkets (the Westside of Sunnyvale-Mountain View, parts of Seattle, Austin) and a headwind on others (the deeper Valley R&D corridor that traditionally housed semiconductor R&D operations). Per Pharmaceutical Technology and the trade press, the AI hyperscaler buildout is partially diverting capital from biotech R&D toward data-center-adjacent R&D and pilot manufacturing — a market-share shift that shapes which submarkets recover first.

Light industrial / contract manufacturing flex is the workhorse — small-bay buildings serving local manufacturers, contract assemblers, and distributors with showroom requirements. The EastGroup Properties (65.5M SF Sun Belt portfolio) and First Industrial (national Tier-1 industrial REIT) benchmark portfolios anchor the institutional comp set. Cap rates run 6.5–7.5%. The reshoring tailwind benefits this cohort indirectly — contract manufacturers serving the Tier-1 OEMs cluster around the advanced-manufacturing anchors, and the demand for 50K–150K SF shallow-bay multi-tenant product has held up better than the demand for the largest distribution boxes.

Specialty flex — data center adjacent, life-sciences manufacturing, advanced energy is the emergent fourth population. Edge data-center and AI-inference colocation in 50K–200K SF flex bays. Life-sciences manufacturing — the CDMO and contract-pharma sites that sit between R&D and full GMP commercial production — in 80K–300K SF flex with selective clean-room build-out. Advanced-energy R&D and pilot production for battery, hydrogen, and grid-scale energy storage tenants. Each is a discrete underwriting case; the common thread is high TI, longer-than-typical-flex lease terms, and a buyer pool that pulls toward specialist sponsors.

Flex operational reality

Flex buildings typically run 50K–300K SF total with 5K–30K SF suites. The leasing rhythm is different from distribution: 6–12 month vacancy is normal between tenants versus 3–6 months for distribution. Parking ratios run 2.5–4.5 spaces per 1,000 SF — closer to office than to distribution's 1.0–2.0. TI burn on rollover is the dominant operating expense, and for biotech R&D flex, TI on re-lease can run $150–250 PSF on lab fit-out before any tenant-specific specification. The institutional flex underwriter spends most diligence time on the rent roll, the rollover schedule, the submarket comp set, and the TI burn forecast — the same operational discipline a multi-tenant office underwriter applies, adjusted for the industrial-spec reality.

The Biotech R&D Flex Reset

The fresh wedge on the flex side is the 2024–2026 biotech reset. The institutional biotech submarkets expanded aggressively from 2018 through 2021 against a venture and IPO-funded biotech wave that pulled forward years of demand. The 2022–2024 funding contraction and the post-2024 demand pullback have left the lab market structurally oversupplied in the secondary submarkets and softer than expected even in the prime. The Q4 2025 / Q1 2026 vacancy prints are the cleanest measurable proof.

The Q4 2025 / Q1 2026 vacancy reality

Per Cushman & Wakefield and JLL Life Sciences research circulating in the late 2025 and Q1 2026 prints, Greater Boston lab vacancy is approximately 26.7% — the highest reading on record for the nation's deepest biotech submarket. East Cambridge — historically the tightest US lab submarket — prints 19.7% vacancy. Boston city proper carries approximately 42% lab vacancy. Cambridge as a whole is approximately 24%. Per the Boston Globe / Boston.com coverage from March 2025, the Massachusetts biotech slump has produced unleased lab space, plunging valuations, and layoffs across the sector. The reading has not materially reversed in the Q1 2026 prints.

The Takeda sublease and the anchor-recommit counter-story

Per FiercePharma and BioPharma Dive coverage, Takeda has subleased approximately 450K SF in Cambridge as part of a global footprint consolidation. That single sublease is, on its own, more than 2% of the institutional Kendall lab inventory. Other large pharma footprints in Cambridge — Sanofi, Novartis, Pfizer, Moderna — have rationalized parts of their footprints in parallel. The bifurcation cuts the other way too: Biogen has recommitted to Kendall for its global headquarters, and several mid-cap biotechs have expanded into Cambridge sublease availability at compelling rents. The Q1 2026 institutional read is that Kendall is bifurcating between recovering / re-tightening prime and softening secondary, with the sublease overhang concentrated in 2018–2022 deliveries.

The basis reset and the long-term thesis

Kendall asking rents had hit $140 PSF+ in the prime at the 2021 peak. The 2026 effective rent on re-leasing is materially below that print, and cap rates have moved from the 4.5–5.25% prime band to a 6.5–7.5% effective range on the deals trading in Q1 2026. Per Phase 3 Real Estate's Q1 2026 Kendall acquisition (covered in Boston Real Estate Times), the institutional appetite for repositioned lab in Kendall Square at a reset basis is real — Alexandria, IQHQ, Longfellow, BioMed Realty have all been active on the bid side. The institutional read: the long-term thesis on Kendall is intact (it is structurally the world's deepest biotech submarket), and the 2024–2026 reset has reset basis, not fundamentally re-priced the long-term sector tailwind. The bet on a Kendall biotech R&D flex acquisition in 2026 is on re-leasing into the recovery at the reset basis.

The secondary submarkets — suburban Boston, Research Triangle Park, suburban San Diego, NJ — have a longer absorption cycle ahead. Per Cushman's Q1 2026 Life Sciences print, healthier funding and stronger M&A and licensing have begun to support a return in expanding pharma manufacturing and R&D construction; but the velocity of secondary-submarket recovery lags the prime by 12–24 months in the consensus debt-broker view.

Capital Stack Reality

The capital stack on manufacturing CTL is structurally distinct from the capital stack on flex / R&D. Both are distinct from core logistics. The institutional underwriter sizing debt or screening equity requirements on a manufacturing or flex deal has to read the stack against the right comp set, not the industrial-default comp set.

Manufacturing CTL acquisition

The manufacturing CTL acquisition competes against the net-lease bid more than the core-industrial bid. The expected senior debt is balance-sheet life-co or insurance paper at 55–65% LTV, 10–25 year fixed rate matched to the lease term — structured like a CTL bond. Equity capital sources: net-lease REITs (Realty Income, W. P. Carey, STORE Capital, Spirit Realty), private net-lease funds (LCN Capital Partners, Oak Street / Blue Owl, Brookfield's net-lease platform), private REITs in the BREIT / BPP cohort, and the institutional sale-leaseback market. Sale-leaseback volume to manufacturers spiked through 2024–2025 as companies unlocked balance-sheet capital to fund reshoring capex; this is a meaningful seller-side pipeline that the manufacturing CTL bidder pool actively works.

Manufacturing build-to-suit development

BTS manufacturing development is overwhelmingly forward-leased — the development risk transfer to the tenant is what makes the project bankable. The Prologis-GIC $1.6B JV is the institutional template. Debt is construction-to-perm balance-sheet at 60–65% LTC with a life-co lead, with takeout sized to the lease term. Equity from open-ended core funds and sovereign capital — GIC, ADIA, Norges, the Canadian pension cohort — alongside the institutional industrial REIT balance sheet. The Trammell Crow, Hines Industrial, Stonemont, and Realterm developer cohort is active.

Flex / R&D multi-tenant acquisition

The flex / R&D multi-tenant acquisition sits in the value-add industrial / industrial-flex bid. Debt is from regional banks and debt funds at 60–70% LTV, 5–7 year terms with extension options. Equity from value-add funds, private REITs in the BREIT-style cohort, and family-office capital. Stonemont's IOS specialization, Realterm's transportation-adjacent specialization, and STAG Industrial's smaller-tenant industrial book are reference platforms for the institutional comp set.

Biotech R&D flex specialist stack

Biotech R&D flex has its own specialized capital stack. Senior debt from life companies and the large money-center banks active in life sciences (JPMorgan, Wells Fargo, Bank of America, Goldman). Equity from life-sciences specialist sponsors — Alexandria Real Estate Equities, IQHQ, Longfellow, BioMed Realty (Blackstone), Healthpeak's life-sciences book, Ventas's life-sciences book, the Tishman Speyer / Breakthrough Properties JV. The 2024–2026 reset has hit value but the institutional bid has not disappeared — transaction velocity is below the 2021 peak but well above the 2023–2024 trough on the prime submarket comp set.

Deal A — Phoenix Semiconductor CTL

The first worked example. An advanced-manufacturing CTL acquisition in the North Phoenix TSMC cluster. The asset profile follows the institutional spec for a Tier-1 semiconductor equipment supplier facility: 240,000 SF on 40 acres, 2024 vintage, 50 ft clear height, 1,200 PSF floor load, 4 MW utility service with redundant feeds, eight dock doors plus two drive-ins, 15% office buildout. The tenant is a Tier-1 semiconductor equipment manufacturer at BBB+ corporate credit on a 15-year NNN with two 5-year FMV options and 2.0% annual escalators. Lease commencement 2024, base rent $18.00 PSF NNN, base-year NOI $4.32M. Tenant equipment investment in the facility is approximately $1.5B; landlord TI is zero because the tenant delivered the clean-room build-out as tenant capex. The deal is on the market at a 6.10% cap rate, implying a $70.8M purchase price ($295 PSF).

Deal A worked example — illustrative, not deal-specific. The Phoenix advanced-manufacturing CTL profile underwrites as net-lease credit. The cap rate sits 50–75 bps tighter than light-industrial flex in the same submarket because the tenant credit and the equipment moat carry the deal.

The institutional read on Deal A is that this is a credit underwrite, not a real-estate underwrite. The diligence workload is dominated by the tenant credit memo, the lease document, and the strategic-role-of- facility analysis. Replacement-cost residual is a secondary check; the primary case for the cap rate is the BBB+ tenant credit, the 15-year remaining term, and the strategic role of the facility within the tenant's Phoenix-cluster footprint. The renewal probability at year 15 is high because the $1.5B of tenant equipment capex is not portable — the tenant cannot relocate without writing off the equipment investment. The deal trades into the net-lease bidder pool: Realty Income, W. P. Carey, the private net-lease funds, and the industrial CTL sleeves at the large sovereign capital pools (GIC, ADIA, Norges). The traditional industrial REIT bid (Prologis, Brookfield, EastGroup) is structurally less competitive on this deal because the asset profile pulls toward the net-lease comp set and away from the multi-tenant industrial bid.

Deal B — Cambridge Biotech R&D Flex

The second worked example. A Cambridge Kendall Square biotech R&D flex acquisition at the post-2024 reset basis. 180,000 SF urban-infill flex / R&D building, 1.2-acre site, 18 ft clear height (typical for lab/R&D flex), 35% office buildout, 65% lab build-out, 2018 vintage with a 2023 partial renovation. Six tenants — biotech R&D and contract-pharma R&D — in 12K–45K SF suites on 5-year average remaining terms (5-year average original terms) with 3% annual escalators. In-place rent averages $52 PSF gross; stabilized economic occupancy 88%, reflecting the post-2024 Cambridge softening. NOI of approximately $5.4M. The deal is on the market at a 6.85% cap rate, implying a $78.8M price ($438 PSF). Cap rate at the 2021 Kendall peak was 4.50–5.25%; the 6.85% Q1 2026 print is the basis-reset reality.

Deal B worked example — illustrative, not deal-specific. The Cambridge biotech R&D flex profile underwrites as multi-tenant real estate. The cap rate sits 75 bps wider than Deal A's CTL print because the tenant credit is diffuse, the rollover is operational, and the TI burn on re-lease is meaningful. The bet is on re-leasing into the recovery at a reset basis.

The institutional read on Deal B is that this is a real-estate underwrite, not a credit underwrite. The diligence workload is dominated by the submarket comp set, the rent roll, the rollover schedule, the re-leasing velocity analysis (months from move-out to lease commencement in the comp set), and the TI burn forecast on rollover. Tenant credit is a secondary concern because the multi-tenant structure spreads the risk across six counterparties — biotech tenants are often pre-revenue, but no single tenant carries more than 25–30% of the rent. The deal trades into the life-sciences specialist bidder pool: Alexandria, IQHQ, Longfellow, BioMed Realty (Blackstone), Healthpeak's life-sciences book, and the value-add industrial-flex funds. The traditional industrial REIT bid is structurally less competitive on this deal because the asset profile pulls toward the life-sciences-specialist comp set and away from the multi-tenant flex bid that doesn't underwrite lab fit-out.

The Two-Deal Payoff

Two deals labeled "industrial." Neither underwrites like the other. The side-by-side comparison is the article's payoff — it makes the institutional distinction visceral in a way that no taxonomy table can.

The two-deal payoff. Same industrial label, opposite underwriting frameworks, 75 bps of cap rate between them, buyer pools that barely overlap. The 2024–2026 macro supports the manufacturing CTL side (with the IoT Analytics / Census temper); the 2024–2026 biotech reset shapes the flex/R&D basis on the other.

The takeaway is operational, not theoretical. The 2026 acquisitions team scanning a fresh OM on a manufacturing or flex deal has to make the same first call the medical-office team makes when reading the rent roll: is this a credit instrument or an operational asset? If the lease document is the artifact you spend two hours reading, it is a credit underwrite. If the rent roll is the artifact, it is a real-estate underwrite. The cap rate, the IRR, the buyer pool, the debt structure, the diligence workload, and the institutional comp set all fall out of that first call. The parallel article on the MOB side (single-tenant credit vs multi-tenant medical office) walks the same bifurcation in a different sector.

Six Mistakes Practitioners Make

• Anchoring on the announced-volume figure without the delivery-side temper. The Reshoring Initiative 244K-jobs-in-2024 figure and the SIA $645B+ semiconductor announcement number are real, and they read like a one-way tailwind for manufacturing CRE. The IoT Analytics / Census construction-spending data, the Intel Ohio slippage, the Samsung Taylor pause, the Stellantis €22.2B reset, and the Reshoring Initiative's own 174K-projected-jobs-2025 figure are the necessary other half. Underwrite the announcement-side at a discount — many institutional acquirers use a 50–70% delivery probability on multi-year manufacturing announcements when sizing future absorption.

• Using core-industrial cap rates on manufacturing CTL. The core-logistics Class A cap rate (5.5–6.5%) is the wrong comp set for a Tier-1-credit advanced-manufacturing CTL. The net-lease bid (5.75–6.75% on BBB+ credit with long WALT) is the right comp set. Using core-logistics cap rates undervalues the asset on the bid side and miscalibrates the buyer pool. Per Bridge Investment Group and the broader net-lease literature, the institutional net-lease bid is its own discipline; bring that comp set into the pricing, not the core-industrial one.

• Underestimating the TI / clean-room build-out cost on advanced manufacturing. $300–1,000+ PSF on advanced clean rooms (ACH Engineering, Cushman fit-out guide). Many institutional underwriters carry $50–100 PSF as the default industrial TI figure; that is the distribution figure, not the manufacturing figure. On BTS deals the tenant typically carries the equipment, but landlord shell costs scale with the power, floor-load, vibration, and chemical-handling spec — not the four-walls cost. Size the shell against the spec, not the default.

• Treating biotech R&D flex as a uniform sector. The Q1 2026 dataset bifurcates between recovering / re-tightening prime (Kendall, SSF, San Diego UTC) and softening secondary (suburban Boston, Research Triangle Park, suburban San Diego, NJ). A Kendall acquisition at the reset basis has a meaningfully different lease-up curve than a suburban Boston acquisition at a wider cap. Don't average the sector; read the submarket.

• Ignoring power as the binding site-selection constraint. Per ULI/PwC and Prologis, larger industrial users are encountering 1–2 year delays for sufficient power access in many markets. For advanced manufacturing requiring 2–5 MW (or 50–200+ MW for a leading-edge semiconductor fab), power availability is now ahead of land cost and incentive depth as the threshold criterion. Underwriting a 2026 manufacturing acquisition without explicit power-interconnection diligence is a meaningful institutional risk.

• Mis-sizing landlord TI burn on flex / R&D rollover. Multi-tenant flex carries meaningful TI burn on rollover — $80–250 PSF on flex, $150–500 PSF on lab. The 2018 flex underwrite assumed lower TI; the 2026 underwriting environment requires the full lab fit-out range on biotech R&D rollover, particularly for buildings inheriting non-fungible tenant-specific lab configurations. The TI burn is the dominant operating expense on the model and the most-often underestimated.

From Manufacturing/Flex to Apers

The 2026 acquisitions team pulling an OM on a manufacturing CTL or a flex/R&D portfolio runs both deal types through the same institutional model.

AQ-401 Industrial Warehouse / Distribution Center Model underwrites industrial acquisitions with a 10-year cash flow projection: acquisition basis, BTS construction cost or shell capex, lease-up curve with concession burn for multi-tenant deals, TI burn on lab or specialty fit-out, OpEx with utility and tax detail, NOI bridge, cap-rate sensitivity, and debt sizing. The Deal A and Deal B worked examples in this article both flow cleanly through AQ-401 — the CTL underwrite by overlaying the net-lease module on the AQ-401 baseline; the flex/R&D underwrite by overlaying the multi-tenant lease-rollover module. The same model framework, two operational specializations.

For manufacturing CTL deals the spreadsheet work concentrates on tenant credit, lease-term cash-flow projection, year-15 renewal sensitivity, residual-value sanity-check, and power-interconnection / environmental risk overlays. For flex / R&D deals the work concentrates on rent-roll diligence, WALT (unit-weighted and space-weighted), rollover schedule, lease-up velocity against the submarket comp set, TI burn forecast on rollover, and the IRR sensitivity to lease-up timing. Both benefit from the AQ-401 structural baseline.

Related Articles

• Industrial Underwriting: Clear Heights, Dock Doors, and the Modern Distribution Spec — the distribution-side baseline that this article's spectrum table reads against; the structural comp on the real-estate-underwriting end of the spectrum.

• Logistics & Distribution: E-commerce Sensitivity and the Last-Mile Spec — the cluster pillar covering the distribution and last-mile populations that sit at the real-estate-underwriting end of the industrial continuum.

• Cold Storage: Specialized Modeling, Tenant Credit, and the Modern Refrigerated Spec — the specialty-industrial cousin to flex/R&D, with its own tenant-credit and TI-burn operational discipline.

• Data Centers: Power Pricing, PUE, and the Hyperscaler Build-to-Suit — the most power-intensive industrial-adjacent typology, where the 2–5 MW manufacturing threshold scales to 50–500+ MW and the underwriting overlaps both CTL and operational-flex frameworks.

• Trophy vs Class A vs Class B Office: The 2026 Stratification — the parallel bifurcation discipline on the office side. Same institutional read, different sector: "office" is no longer a single category; neither is "industrial."

• Medical Office: Single-Tenant Credit vs Multi-Tenant WALT — the credit-vs-operational bifurcation walked on a different asset class. Direct analog to the manufacturing CTL vs flex/R&D distinction in this article.

• IRR Sensitivity Analysis and Stress Testing — the returns machinery that converts stabilized NOI into a levered IRR and stress-tests it against the lease-up timing, cap-rate exit, and rollover-velocity assumptions both deals in this article depend on.